Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine

Present status of human papillomavirus vaccine development and implementation

(2015) Rolando Herrero et al.   LANCET ONCOLOGY

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

(2015) Elmar A. Joura et al.   NEW ENGLAND JOURNAL OF MEDICINE

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

(2014) K Kavanagh et al.   BRITISH JOURNAL OF CANCER

Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18

(2014) Darron Brown et al.   VACCINE

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study

(2014) Mark H Einstein et al.   Human Vaccines & Immunotherapeutics

Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot

(2014) Johannes Trück et al.   Human Vaccines & Immunotherapeutics

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

(2013) M. Safaeian et al.   Cancer Prevention Research

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

(2013) Simon R. M. Dobson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials

(2013) Paula N. Walsh et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010

(2013) Lauri E. Markowitz et al.   JOURNAL OF INFECTIOUS DISEASES

Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)

(2013) Pam Sonnenberg et al.   LANCET

Clinical trials of human papillomavirus vaccines and beyond

(2013) Matti Lehtinen et al.   Nature Reviews Clinical Oncology

A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls

(2013) Eve Draper et al.   PLoS One

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

(2013) D. Mesher et al.   VACCINE

Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial

(2013) Mel Krajden et al.   VACCINE

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses

(2013) Mahboobeh Safaeian et al.   Human Vaccines & Immunotherapeutics

Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

(2012) S. N. Tabrizi et al.   JOURNAL OF INFECTIOUS DISEASES

Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis

(2012) Nicolas Van de Velde et al.   JNCI-Journal of the National Cancer Institute

Understanding and learning from the success of prophylactic human papillomavirus vaccines

(2012) John T. Schiller et al.   NATURE REVIEWS MICROBIOLOGY

Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination

(2012) Kinga K. Smolen et al.   VACCINE

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

(2011) Aimée R. Kreimer et al.   JNCI-Journal of the National Cancer Institute

A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection

(2011) S. Longet et al.   JOURNAL OF VIROLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

(2011) Eve Draper et al.   VACCINE

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

(2011) Troy J. Kemp et al.   VACCINE

In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection

(2010) Patricia M. Day et al.   Cell Host & Microbe

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

(2010) Silvia de Sanjose et al.   LANCET ONCOLOGY

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine

(2010) Joseph G. Dauner et al.   VACCINE

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Vaccines: Correlates of Vaccine‐Induced Immunity

(2008) Stanley A. Plotkin   CLINICAL INFECTIOUS DISEASES

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years

(2008) Tiina Petäjä et al.   JOURNAL OF ADOLESCENT HEALTH

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

(2008) Troy J. Kemp et al.   VACCINE